Mar 21, 2018 - The broad market is still trying to make up its mind about the overall direction after another consolidation day. Celgene showed confidence in the tau hypothesis of Alzheimer’s disease, AD by signing
Mar 19, 2018 - The Zacks Analyst Blog Highlights: Biogen, AbbVie, Novartis, Teva and Celgene
Mar 18, 2018 - Q4 2017 had record revenue, boosted by Spinraza ramp.Expansion beyond MS to Alzheimer’s and other neural diseases would be transformative.Biogen's goal is to become the “fastest-growing large-cap biot
Mar 16, 2018 - Multiple Sclerosis (MS) is a promising space but risks continue to persist with the recent withdrawal of Zinbryta.
Mar 15, 2018 - Ronald Muhlenkamp's Largest Buys of the 4th Quarter, Stocks: PHM,THO,AZO,EPD,CE,ADS,BIIB, Pioneer Investments,Joel Greenblatt, release date:Mar 15, 2018
Mar 14, 2018 - The combination of disruptive new discoveries coupled with burgeoning demand thanks to the aging demographics of the world’s population sets the biotech space for a potential virtuous long-term cycle.
Mar 14, 2018 - 6 Five-Star Quality Companies for 2018, Stocks: BIIB,CERN,EW,JKHY,NTES,TYL,BAX, Warren Buffett, Ron Baron, Richard Pzena, release date:Mar 14, 2018
Mar 14, 2018 - Bull of the Day: Regeneron (REGN)
Mar 14, 2018 - The biotech sector was in focus last week with key news - Orexigen going bankrupt, Biogen acquires asset from Pfizer, Regeneron cuts Praluent price among others.
Mar 14, 2018 - The biotech has a lot of promise -- but some big risks.